Homocysteine plasmatic status in patients with psoriasis

Richetta, Antonio Giovanni; Mattozzi, Carlo; Macaluso, Laura; Cantisani, Carmen; Giancristoforo, Simona; D'Epiro, S; Salvi, Monica; Scarnò, Marco; Calvieri, Stefano

doi:10.1684/ejd.2011.1455

Cited by 12 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum homocysteine levels in patients with psoriasis were positively correlated with PASI. Several researchers have demonstrated significantly increased homocsyteine levels in the psoriasis patients compared with controls [19, 47–52]. However, Cakmak et al [53] in the Central Anatolia Region of Turkey, the same region as in our study, reported no significant difference in homocysteine levels between psoriasis patients and controls, although serum homocysteine levels correlated with PASI, in agreement with our findings.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis

Ataseven¹,

Keşli

Kurtipek³

et al. 2014

Disease Markers

View full text Add to dashboard Cite

Background. Chronic inflammation may play a role in psoriasis pathogenesis. Lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1 (sTNFR-1), interleukin-6, homocysteine, and uric acid are inflammatory and/or biochemical markers. However, both the roles of these markers and the pathogenesis of psoriasis are unknown. Objective. The aim of this study was to investigate serum levels of lipocalin 2, clusterin, sTNFR-1, interleukin-6, homocysteine, and uric acid in patients and controls groups. Methods. Fifty-six patients with psoriasis and 33 healthy controls were included in the study. Serum concentrations of the markers were evaluated by ELISA. The Psoriasis Area and Severity Index (PASI) was evaluated in all psoriasis patients. Body mass index (BMI) was calculated by dividing weight (kg) by height (m) squared. Results. The serum value of lipocalin and sTNFR-1 were significantly higher in psoriasis patients than in controls (resp., P < 0.001, P < 0.05). The others showed no significant differences between psoriasis and the control groups (all of them P > 0.05). The mean PASI score in the patient group was 8.3 ± 6.5. Conclusions. These findings suggest that lipocalin 2 and sTNFR-1 might play a role in the pathogenesis of psoriasis and can be used as markers of the disease.

show abstract

Section: Discussionsupporting

confidence: 91%

“…The difference in findings may be related to regional and/or genetic differences between psoriasis patients. Few studies have shown a relationship between homocysteine levels and PASI [48, 52, 53]. The increased cardiovascular risk with increasing psoriasis severity might be due to homocysteine.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis

Ataseven¹,

Keşli

Kurtipek³

et al. 2014

Disease Markers

View full text Add to dashboard Cite

show abstract

“…High levels of homocysteine damage endothelial cells, promote clot formation, decrease blood vessel flexibility, and thus increase aortic stiffness 18. Elevated homocysteine may be yet another aspect of psoriasis that contributes to the increased risk of cardiovascular disease;15 however, the data on whether or not higher homocysteine levels correspond to the severity of psoriasis are conflicting 16,19,20…”

Section: Cardiovascular Disease and Risk Factorsmentioning

confidence: 99%

Psoriasis and comorbidities: links and risks

Ni¹,

Chiu²

2014

CCID

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting approximately 2% of the population worldwide. In the past decade, many studies have drawn attention to comorbid conditions in psoriasis. This literature review examines the epidemiological evidence, pathophysiological commonalities, and therapeutic implications for different comorbidities of psoriasis. Cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease, cancer, anxiety and depression, and inflammatory bowel disease have been found at a higher prevalence in psoriasis patients compared to the general population. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented to most effectively manage psoriasis patients.

show abstract

“…Hyperhomocysteinemia, a well‐known cardiovascular risk factor , has been described in psoriasis patients . This finding has been commonly explained by the low levels of folic acid in this population . COMT produces S‐adenosylhomocysteine, a homocysteine (hcy) precursor, and high activity COMT variants were associated with elevated plasma total hcy and COMT inhibitors with the reverse .…”

Section: Discussionmentioning

confidence: 99%